Thursday, April 12, 2012
Phenotypic screening is making a comeback in drug discovery,
as some researchers have concluded that reductionist approaches such as
target-based screening are useful but may also limit the breadth of new
findings. Although companies such as Novartis AG and GlaxoSmithKline plc are
embracing this resurgence, others such as Roche's Genentech Inc. unit remain focused
on target-based screening.
phenotype to target
Staying on target
Changing the equation
Kotz, J. SciBX 5(15);
Published online April 12, 2012
1. Swinney, D.C. &
Anthony, J. Nat. Rev. Drug Discov.
10, 507-519 (2011)
2. Barretina, J. et al. Nature 483, 603-607 (2012)
3. Laggner, C. et al. Nat. Chem.
Biol. 8, 144-146 (2011)
4. Plouffe, D. et al. Proc. Natl.
Acad. Sci. USA 105, 9059-9064 (2008)
5. Gamo, F.-J. et al. Nature 465, 305-310 (2010)
6. Guiguemde, W.A. et al. Nature 465, 311-315 (2010)
Genentech Inc., South San Francisco, Calif.
GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K.
Medicines for Malaria Venture, Geneva, Switzerland
Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland
Novartis Institute for Tropical Diseases, Singapore
Novartis Institutes for BioMedical Research, Boston, Mass.
(SIX:ROG; OTCQX:RHHBY), Basel, Switzerland
St. Jude Children's Research Hospital, Memphis, Tenn.
University of California, San Francisco, Calif.
The University of North Carolina at Chapel Hill, Chapel Hill, N.C.